Safety assessment of food and feed from biotechnology-derived crops employing RNA-mediated gene regulation to achieve desired traits: A scientific review  by Petrick, Jay S. et al.
Regulatory Toxicology and Pharmacology 66 (2013) 167–176Contents lists available at SciVerse ScienceDirect
Regulatory Toxicology and Pharmacology
journal homepage: www.elsevier .com/locate /yr tphSafety assessment of food and feed from biotechnology-derived crops
employing RNA-mediated gene regulation to achieve desired traits: A scientiﬁc
review
Jay S. Petrick a,⇑, Brent Brower-Toland a, Aimee L. Jackson b, Larry D. Kier c
aMonsanto Company, 800 N. Lindbergh Blvd, St. Louis, MO 63167, USA
b Jackson BioConsulting, San Diego, CA 92130, USA
c16428 CR 356-8, Buena Vista, CO 81211, USAa r t i c l e i n f o
Article history:
Received 28 September 2012
Available online 2 April 2013
Keywords:
Food safety
Genetically modiﬁed
Biotechnology-derived plant
RNA interference
RNAi
siRNA
Comparative safety assessment0273-2300  2013 Elsevier Inc.
http://dx.doi.org/10.1016/j.yrtph.2013.03.008
Abbreviations: CRISPR, clustered regularly interspa
dsRNA, double-stranded RNA; FDA, food and drug adm
lipoprotein; miRNA, microRNA; mRNA, messenger R
economic cooperation and development; RdRP, RNA-
RISC, RNA-induced silencing complex; RNAi, RNA in
RNA; shRNA, short hairpin RNA; siRNA, small interfer
WHO, World Health Organization.
⇑ Corresponding author. Fax: +1 314 694 5071.
E-mail address: jay.s.petrick@monsanto.com (J.S. P
Open access under CC BYa b s t r a c t
Gene expression can be modulated in plants to produce desired traits through agricultural biotechnology.
Currently, biotechnology-derived crops are compared to their conventional counterparts, with safety
assessments conducted on the genetic modiﬁcation and the intended and unintended differences. This
review proposes that this comparative safety assessment paradigm is appropriate for plants modiﬁed
to express mediators of RNA-mediated gene regulation, including RNA interference (RNAi), a gene sup-
pression mechanism that naturally occurs in plants and animals. The molecular mediators of RNAi,
including long double-stranded RNAs (dsRNA), small interfering RNAs (siRNA), and microRNAs (miRNA),
occur naturally in foods; therefore, there is an extensive history of safe consumption. Systemic exposure
following consumption of plants containing dsRNAs that mediate RNAi is limited in higher organisms by
extensive degradation of ingested nucleic acids and by biological barriers to uptake and efﬁcacy of exog-
enous nucleic acids. A number of mammalian RNAi studies support the concept that a large margin of
safety will exist for any small fraction of RNAs that might be absorbed following consumption of foods
from biotechnology-derived plants that employ RNA-mediated gene regulation. Food and feed derived
from these crops utilizing RNA-based mechanisms is therefore expected to be as safe as food and feed
derived through conventional plant breeding.
 2013 Elsevier Inc. Open access under CC BY-NC-ND license.1. Introduction
RNA interference (RNAi) is an RNA-based mechanism that mod-
ulates endogenous gene expression in eukaryotes including plants,
insects, fungi, nematodes, and mammals. Because RNAi is a widely
occurring biological process, the RNA molecules that mediate this
mechanism are a ubiquitous component of the diet for animals
including humans. RNAi is mediated by small RNA molecules that
bind to and suppress transcription and/or translation of speciﬁc
messenger RNAs (mRNAs); speciﬁcity is driven by base pairing be-
tween target mRNAs and these small RNAs. Because of the speciﬁc-ced short palindromic repeat;
inistration; LDL, low density
NA; OECD, organisation for
dependent RNA polymerase;
terference; rRNA, ribosomal
ing RNA; tRNA, transfer RNA;
etrick).
-NC-ND license.ity of RNAi, there is great interest in application of this mechanism
for crop improvement and for development of human therapeutics.
Based on evidence supporting continual exposure to dietary RNA
(including siRNAs, miRNAs, and longer dsRNAs) and biological bar-
riers that limit uptake and biological activity of ingested RNA, there
is no reason to expect that consumption of foods or feeds from bio-
tech crops employing traits produced through an RNAi-based
mechanism or other RNA-mediated mechanism are any less safe
than their conventional counterparts. However, to realize the po-
tential for applications of these mechanisms in agricultural bio-
technology, it is necessary to establish scientiﬁcally sound
principles for evaluating their safety in crop plants. Herein we con-
sider the weight-of-the-evidence supporting the safe use of RNAi
in crop plants in the context of the current paradigm for evaluating
the safety of biotechnology-derived crops (referred to throughout
as biotech crops). This evidence is also considered in the context
of one study that suggested oral activity of a plant miRNA after
dietary consumption (Zhang et al., 2012a). Based on the
weight-of-the-evidence for RNA dietary safety and the robust nat-
ure of the current internationally accepted principles for the safety
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ples are applicable to crops modiﬁed using RNA-based mecha-
nisms such as RNAi.2. RNAi: Background and plant applications
2.1. General features of RNAi
Gene suppression was ﬁrst observed in plants as a cellular
mechanism for the recognition and degradation of foreign RNA
including viral RNA (Dougherty et al., 1994; Napoli et al., 1990).
Fire, Mello, and colleagues deﬁned the RNA-mediated mechanism
of gene suppression (i.e., RNAi) in nematodes (Fire et al., 1998),
and RNAi-mediated gene suppression has since been observed in
fungi, worms, insects, and mammals (Brodersen and Voinnet,
2006; Dykxhoorn et al., 2003; Ghildiyal et al., 2008; Jones-Rhoades
et al., 2006; Li and Liu, 2011; Mallory and Vaucheret, 2006; Sandy
et al., 2005; Vazquez, 2006). Prokaryotes also utilize RNA-mediated
gene silencing through the CRISPR system that is analogous to, but
mechanistically distinct from, RNAi (Wiedenheft et al., 2012).
Based on these observations, it is apparent that modulation of gene
expression through RNA-mediated mechanisms is nearly
ubiquitous.
The triggers for RNAi-mediated gene suppression are small dou-
ble-stranded RNAs (dsRNAs) of 21–27 nucleotides; these small
RNAs include small interfering RNAs (siRNAs) and microRNAs
(miRNAs) (Hammond, 2005; Zamore et al., 2000). siRNAs and miR-
NAs are derived from processing of longer dsRNA sequences that
do not encode proteins. In plants, biogenesis of siRNAs and miRNAs
from precursor dsRNAs involves multiple Dicer-like proteins (Liu
et al., 2009), endonucleases that cleave longer dsRNAs. Mature siR-
NA duplexes contain an interfering antisense or guide strand com-
plementary to a target mRNA sequence and a passenger strand
(Caplen et al., 2001; Elbashir et al., 2001; Zamore et al., 2000).
RNAi-mediated gene suppression involves incorporation of the
guide strand into an RNA-induced silencing complex (RISC) with
concomitant degradation of the passenger strand (Tomari and Za-
more, 2005). RNAi-mediated gene suppression occurs through
either mRNA degradation or translational inhibition (Bartel,
2009; Carthew and Sontheimer, 2009; Fabian et al., 2010; Guo
et al., 2010; Huntzinger and Izaurralde, 2011).Fig. 1. Biological barriers to uptake and activity of ingested RNA.2.2. Differences in RNAi mechanisms in different kingdoms
Although the general mechanism of RNAi is conserved across
eukaryotes, there are some important phylogenetic differences. A
general distinction is that plant miRNAs are usually perfectly or
nearly perfectly complementary to their target genes and induce
direct mRNA cleavage by RISC, whereas miRNAs in animals trigger
either translational repression (Fabian et al., 2010) or target mRNA
cleavage (Guo et al., 2010; Huntzinger and Izaurralde, 2011). There
is some evidence, however, that miRNAs can also act in the trans-
lationally inhibitory mode in plants (Brodersen et al., 2008). An-
other aspect of RNAi observed in nematodes and plants is
intercellular spreading of gene suppression. Classic examples of
this phenomenon are systemic transport of viral resistance from
a local site of infection to distant sites in plants and systemic
spreading observed in Caenorhabditis elegans (Jose and Hunter,
2007). The phenomenon of intercellular spreading of RNAi appears
to be restricted to plants, fungi, and a subset of invertebrate species
(Jose and Hunter, 2007; Voinnet, 2005). Intercellular spreading
may be attributed to the activity of RNA-dependent RNA polymer-
ase (RdRP) that is present in plants, worms, and perhaps other
invertebrates but does not appear to be present in Drosophila or
vertebrates (Tomari and Zamore, 2005).Nematodes also exhibit intercellular and systemic transport of
RNA molecules, processes not observed to any signiﬁcant extent
in mammals. RNAi-mediated gene suppression is induced in C. ele-
gans by soaking the worms in siRNA-containing solutions (Maeda
et al., 2001; Tabara et al., 1998), by feeding bacteria expressing
an siRNA to C. elegans (Newmark et al., 2003; Timmons et al.,
2001), or by injecting RNA isolates from siRNA producing plants
into worms (Boutla et al., 2002). There have also been demonstra-
tions of RNAi-mediated gene suppression in larvae of certain spe-
cies of insects and nematodes upon feeding of plant material
engineered to produce dsRNAs targeting genes in these organisms
(Baum et al., 2007; Fairbairn et al., 2007; Huang et al., 2006; Mao
et al., 2007; Yadav et al., 2006). Although there has been specula-
tion that ampliﬁcation of the RNAi signal and systemic transport
and spreading might be present in mammals under certain envi-
ronmental conditions (Jose and Hunter, 2007), there is no in vivo
evidence for these functions in mammals. Taken together with
the mammalian barriers to uptake of dietary RNA (Depicted in
Fig 1), this information strongly suggests that no adverse effects
should be anticipated in mammals following consumption of die-
tary RNA. This assertion is also discussed below (Section 3.4.5.)
in the context of a publication that indicates possible mammalian
responses to ingested small RNAs.
2.3. Applications of RNAi in plants
Examples of naturally occurring RNA-mediated gene suppres-
sion traits that were selected through conventional breeding in-
clude soybean seed coat color (Tuteja et al., 2004) and maize
stalk color (Della Vedova et al., 2005), both of which are mediated
through suppression of chalcone synthase. Additionally, a conven-
tional low glutelin rice variety resulted from a naturally occurring
insertion of a region into the genome that expresses a long dsRNA
that suppresses glutelin via an RNA-mediated mechanism (Kusaba
et al., 2003). RNA-mediated gene suppression has also been lever-
aged in the production of biotechnology-derived food crops such as
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ripening tomato, and a soybean with altered oil composition (Frizzi
and Huang, 2010; Parrott et al., 2010). RNA-based mechanisms
have also been harnessed to improve crop nutritional values
(Andersson et al., 2006; Regina et al., 2006), reduce allergen levels
(Le et al., 2006), improve agronomic characteristics (Allen et al.,
2004; Ogita et al., 2003), and provide insect protection (Baum
et al., 2007; Gordon and Waterhouse, 2007; Huvenne and Smag-
ghe, 2010; Mao et al., 2007).
Engineering of plants with traits produced via RNA-mediated
gene regulation can be achieved using the same genetic modiﬁca-
tion techniques used in the production of other biotech crops
grown widely today. Plants can be engineered to produce long dsR-
NAs or short hairpin RNAs (shRNAs) that are processed into siRNAs
or miRNAs. Such dsRNA producing constructs are designed to pro-
duce transcripts lacking protein-coding open reading frames and
translation initiation signals necessary for protein production
(Hemmings-Mieszczak and Hohn, 1999; Kozak, 1989). As a result,
RNA transcripts produced from the inserted DNA do not give rise to
a heterologous protein. Use of RNA-mediated gene regulation
(including RNAi-mediated suppression) in biotech crops thus obvi-
ates the need to conduct protein safety assessments (Parrott et al.,
2010).3. Safety assessment of food and feed from plants produced
using RNA-based traits
3.1. Application of current safety assessment approaches to foods from
plants with phenotypes produced through RNA-mediated gene
regulation
A well-deﬁned approach already exists for evaluation of the
safety of agricultural biotechnology products, namely, the compar-
ative safety assessment paradigm (Codex, 2003; Parrott et al.,
2010). This approach is embodied in numerous documents gener-
ated by organizations with international oversight, including the
World Health Organization (WHO) and the Organisation for Eco-
nomic Cooperation and Development (OECD), and forms the
framework for safety assessment of biotechnology-derived crop
products currently sold on the global market. This assessment pro-
cess addresses safety aspects resulting from intended effects of the
genetic modiﬁcation as well as any unintended effects on the plant
that could have resulted from the introduced trait or from the plant
transformation process itself. Commercially available biotech crops
have been assessed for safety and have received regulatory approv-
als utilizing this assessment paradigm. The majority of biotech
crops currently available in the marketplace have been designed
to express one or more proteins that confer some desirable pheno-
type to the plant (e.g., herbicide tolerance or insect protection).
Thus, certain protein-speciﬁc aspects of the existing safety assess-
ment paradigm (e.g., homology of the expressed protein to known
protein toxins and allergens and digestibility) can rationally be
eliminated for traits produced via RNA-mediated gene regulation.
The comparative safety assessment compares the agronomic/
phenotypic characteristics and environmental interactions (e.g.,
crop growth and development, persistence, plant interactions with
symbionts, and plant interactions with diseases and insects) and
compositional characteristics (e.g., key nutrients, anti-nutrients,
and toxins) of the biotechnology-derived crop with those of its
conventional counterpart with a history of safe use (Atherton,
2002; Cockburn, 2002; Codex, 2003; EC, 2003; FAO/WHO, 1996;
FAO/WHO, 2000; ILSI, 2004; Konig et al., 2004; OECD, 2003). Eval-
uation of plant morphology and agronomic and phenotypic charac-
teristics is important from the standpoint of marketability and also
because this assessment provides a robust, yet very sensitive,screen for any unintended effects of the genetic modiﬁcation (Cel-
lini et al., 2004; Cockburn, 2002), which in turn can provide a con-
text for results observed in the compositional and nutritional
analyses. An understanding of the morphological and agronomic
characteristics of a biotech crop compared to its familiar conven-
tional counterpart also provides valuable information for the envi-
ronmental risk assessment as any unintended differences in these
parameters can be assessed for their potential plant pest risk or
their potential impact on the biotic or abiotic environment. These
aspects of the comparative assessment would also apply to crops
with modiﬁcations produced through use of RNAi.
Compositional analysis is a key component of the comparative
safety assessment as this analysis allows for an evaluation of any
unintended changes that may have occurred within the plant as
a result of the genetic modiﬁcation. A series of consensus docu-
ments, prepared under the auspices of the OECD, provide a sum-
mary of the compositional characteristics of a number of crops
with indications of natural variability in key analytes that can be
used to facilitate the comparison of a biotech crop and its conven-
tional counterpart and to assess any compositional differences in
the context of the range of normal variation (OECD, 2001a,b,
2002, 2005). Evidence to date suggests that there is a high degree
of variability in crop compositional data that can be attributed to
natural genotypic and environmental variation and that the impact
of genetic modiﬁcation on compositional variability is negligible
(Harrigan et al., 2010; Herman et al., 2009; Zhou et al., 2011a).
A scientiﬁc evaluation of biotech crop products employing RNA-
mediated gene regulation concluded that the comparative safety
assessment paradigm is appropriate for evaluating the safety of
these crops (Parrott et al., 2010). The safety of biotech crops,
including those produced through RNA-mediated gene regulation,
has been successfully evaluated using the comparative safety
assessment approach as demonstrated by global regulatory
approvals of many biotech crops and the absence of conﬁrmed
safety incidents as adoption of the technology continues to in-
crease (James, 2011). In addition to standard data utilized in the
comparative safety assessment, supplemental data may also in-
clude animal feeding studies. In a number of feeding studies with
rodents, chickens, livestock, and ﬁsh, no difference in nutritional
performance has been observed between feeding biotech crops
and their conventional counterparts, providing additional supple-
mental evidence for the safety of crops developed through agricul-
tural biotechnology (Cockburn, 2002; Flachowsky et al., 2005;
Hollingworth et al., 2003). For example, a biotech wheat with an
RNAi-mediated elevation in amylose content was evaluated in a
13-day rat feeding study with diets containing approximately
50% wheat, and no adverse effects were reported (Regina et al.,
2006). Similarly, in a 90-day rat toxicology study, feeding a biotech
rice variety with an RNAi-mediated elevation in amylose content
elicited no adverse effects at a 70% level of dietary incorporation
(Zhou et al., 2011b). Crops such as the Flavr Savr™ tomato and
the high amylopectin potato utilize RNA-mediated gene regulation,
and animal feeding studies provide supplemental evidence sup-
porting their safety (EFSA, 2006; FDA, 1994; Redenbaugh et al.,
1992). Collectively, the weight-of-the-evidence to date supports
the safety of biotech crops produced through applications of
RNA-mediated gene regulation.
3.2. Differences in assessment of plants that express RNA-producing
constructs and those that express engineered proteins
Biotech crops engineered with RNA-mediated gene suppression
cassettes are fundamentally different from those containing con-
structs encoding heterologous proteins because these constructs
are intended to express only non-coding RNAs and do not encode
protein(s). For plants that express heterologous proteins, the
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introduced protein(s) for any relationship to known protein toxins
and allergens. In vitro digestibility studies of such proteins are also
generally recommended, to evaluate their potential for digestion,
as allergenic and toxic proteins may be refractory to digestion (Ast-
wood et al., 1996). Furthermore, acute toxicity of the expressed
protein is often assessed because toxic proteins tend to act acutely
(Pariza and Johnson, 2001; Sjoblad et al., 1992). Unlike proteins,
that can in some rare cases produce oral toxicity, RNA is not known
to produce oral toxicity (acutely or otherwise) in humans. Accord-
ing to the US FDA, ‘‘Introduced nucleic acids [in biotech crops], in
and of themselves, do not raise safety concerns (FDA, 1992).’’ Fur-
thermore, with regards to RNA-mediated gene regulation in bio-
tech crops, the US FDA goes on to state, ‘‘Thus, for example, the
introduction of a gene encoding an anti-sense ribonucleic acid
(RNA) would not raise concerns about either the gene or the
anti-sense RNA. Any safety considerations would focus on the in-
tended effects of the anti-sense RNA.’’ Given the long history of safe
consumption of nucleic acids such as RNA, acute oral toxicity stud-
ies and evaluation of digestibility of the introduced RNA compo-
nent are therefore not warranted for plants with introduced RNA-
based traits. Any additional studies based on the intended effects of
the dsRNA should be considered as needed, on a case-by-case basis.
3.3. Evaluation of unintended effects in biotech crops with RNA-based
traits
The evaluation of potential unintended effects in biotech crops
(e.g., compositional or agronomic changes) is an important consid-
eration in the comparative safety assessment process (Cellini et al.,
2004). Depending on the target gene, biologically meaningful
changes in gene expression in a genetically modiﬁed plant with a
mode of action based on RNAi could be manifested in downstream
compositional or agronomic/phenotypic changes to the plant (Par-
rott et al., 2010). In addition to the intended changes elicited by the
expressed RNA, there is a possibility that unintended changes in
the plant could result from suppression of genes that were not in-
tended as targets of the expressed dsRNA. These so-called off-tar-
get effects would be identiﬁed as compositional or agronomic/
phenotypic changes that are outside the normal range of variability
for these characteristics in the plant species, and once identiﬁed
must be further assessed for biological signiﬁcance to food and
feed safety. Conventional breeding methods and agronomic/phe-
notypic selection processes that are also used in the event selection
process during the development of biotech crops are stringent
tools that help to eliminate undesirable unintended effects result-
ing from the transformation process (Cellini et al., 2004; Cockburn,
2002; Konig et al., 2004). Furthermore, compositional analysis of
food and feed would likely reveal any unintended effects relevant
to safety or nutrition of the biotech crop (Hollingworth et al.,
2003). There do not appear to be any special considerations that re-
late to development of RNA-based traits as the general transforma-
tion and event selection processes and the comparative safety
assessment processes equally apply.
3.4. Evidence supporting safety of oral exposure to RNA
3.4.1. Natural occurrence of long dsRNAs and small RNAs in plants and
other foods provides a history of safe use
A history of safe consumption of plant-derived RNAs is evi-
denced by the fact that all animal and plant-related foodstuffs con-
tain naturally occurring coding RNAs (e.g., mRNAs) and non-coding
RNAs. Total plant RNA content is about 1 mg/g of plant tissue
(Ivashuta et al., 2009; Lassek and Montag, 1990). Non-coding RNAs
including the highly abundant transfer RNAs (tRNAs) and ribosomal
RNAs (rRNAs), single-stranded antisense RNAs, as well as the miR-NAs and siRNAs that trigger RNAi and their precursor dsRNAs are
found in plants (Gould and Francki, 1981; Hamilton and Baul-
combe, 1999; Vazquez et al., 2004), including plants used for food
such as rice (Fukuhara et al., 1993; Ivashuta et al., 2009; Moriyama
et al., 1996; Osato et al., 2003; Wang et al., 2004), Brassica species
(Cock et al., 1997), Cucurbit species (Yoo et al., 2004), and maize
and soybean (Ivashuta et al., 2009). Long dsRNAs from exogenous
sources are particularly common in plants, including food plants,
due to infection from RNA-containing plant viruses (Gould and
Francki, 1981). Small RNAs derived from longer non-coding RNAs
such as tRNAs and intronic regions may be involved in regulation
of gene expression (Rother and Meister, 2011). Animal-derived
foods are generally richer in RNA than plant-derived foods, and ani-
mal-derived foods are also likely to contribute signiﬁcantly to over-
all RNA consumption (Jonas et al., 2001). Animal-derived foods,
which also have a history of safe consumption, contain siRNAs
and miRNAs that serve a variety of functions, including regulation
of endogenous gene expression (Carthew and Sontheimer, 2009).
The fact that small RNAs are safely consumed in human and
animal diets is demonstrated by the presence of thousands of small
RNAs in rice grain with sequence identity to regions in the human
genome and to several livestock animal genomes (Heisel et al.,
2008). A subset of rice small RNAs have 100% sequence identity
to human transcripts (Ivashuta et al., 2009). Identity between ani-
mal small RNAs is higher than the level of identity between plants
and mammals and therefore animal small RNAs in the diet are
more likely than plant small RNAs to have identity to human tran-
scripts. The safe consumption of small RNAs with a high level of se-
quence identity to human genes and the ubiquitous role of RNAi in
regulation of gene expression in plants and animals demonstrates
a history of safe consumption of small RNAs and, by inference, the
dsRNA precursors from which they are derived.
3.4.2. Dietary exposure to biotech crop small RNAs
As previously stated, total RNA content in plant-derived foods
varies but appears to be on the order of 1 mg/g of tissue (Ivashuta
et al., 2009; Lassek and Montag, 1990). Relative percentages (by
weight) of the major forms of RNA in plants are roughly 80% rRNA,
3–5% mRNA, and 10–15% tRNA, with small RNAs making up less
than 5% of total RNA in plants. Small RNAs in the range of 21–24
nucleotides are present at levels of up to 1.61 lg small RNA/g of
conventional soybean grain (average of 0.66 lg/g of grain) and
comparable amounts are present in grain from conventional corn
and rice (Ivashuta et al., 2009). In tobacco plants engineered to
overexpress a dsRNA targeting mouse caspase under the control
of a constitutive promoter, siRNA levels in leaf composed about
1.5% of total RNA (Chau and Lee, 2007). Due to the intended over-
expression of this dsRNA, this percentage likely represents a high-
er-end estimate of levels of engineered siRNAs in plants. When
taken in the context of the total dietary intake of RNA, the addi-
tional RNA from biotech crops will represent a very small fraction
of total RNA consumed. Therefore, the application of RNA-medi-
ated gene regulation to biotech crops would not meaningfully im-
pact the levels of dietary purine intake (RNA is a purine source)
that can sometimes be associated with aggravation of gout symp-
toms in gout patients (Zhang et al., 2012b).
Data reported by Ivashuta and colleagues (2009) and by Chau
and Lee (2007) were used to make conservative estimates of hu-
man dietary exposure to soy and maize small RNAs from hypothet-
ical RNA-based biotech crops (Table 1). Estimates of the highest
reported (97.5th percentile) consumption of soybean grain and
maize (ﬂour, popcorn, and sweet corn) were obtained from the
WHO’s GEMS/Food Programme (WHO GEMS/Food, 2013). These
values represent a conservative (i.e., high-end) estimate of the
maximum amount of a food that would be consumed in a single
day in any world area and are intended for use in assessing
Table 1
Sample exposures to plant-derived siRNAs from biotech crops and margins of
exposure for humans consuming these agricultural commodities.
Commodity 97.5th percentile commodity
consumption (g/kg/day)1
siRNA Intake
(lg/kg/day)2
Soya bean, Dry
General population 3.03 45
Children 6 6 years 5.55 82
Maize ﬂour
General population 2.04 30
Children 6 6 years 3.16 47
Popcorn
General population 3.33 49
Children 6 6 years 3.33 49
Sweet corn (on-the-cob)
General population 7.16 106
Children 6 6 years 11.52 170
1 Consumption data from WHO/GEMS Food acute 97.5th percentile estimates of
food consumption: http://www.who.int/foodsafety/chem/en/acute_haz-
ard_db1.pdf, accessed January 14, 2013.
2 Assumes 100% of commodity consumed is from a biotech crop with total RNA
levels of 986.6 lg/g grain and that 1.5% of these small RNAs are derived from the
transgene (Chau and Lee, 2007; Ivashuta et al., 2009).
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for both the general population and for children aged six and un-
der. Using the highest reported levels of grain-derived total RNA
per gram of plant tissue observed in the Ivashuta study
(986.6 lg RNA/g grain) and a transgene-derived siRNA level of
1.5% of total RNA as reported by Chau and Lee, total exposures to
construct-derived small RNAs from a putative biotech soybean
product were estimated to be 45 lg/kg/day in the general popula-
tion and 82 lg/kg/day for children aged six and under. Using the
same assumptions cited above for expression levels of plant total
RNA/small RNAs for sweet corn (on-the-cob), the corn commodity
consumed in the highest amounts, dietary exposure to construct-
derived small RNAs from a putative biotech corn product were
estimated to be 106 lg/kg body weight/day in the general popula-
tion and 170 lg/kg body weight/day for children aged six and un-
der. The expression levels of any individual transgene-derived
small RNA sequence would be substantially lower than these esti-
mated total amounts. To contrast, doses as high as 10 mg/kg/day of
a single chemically modiﬁed siRNA are well tolerated in human
clinical trials (Vaishnaw et al., 2010) and siRNA doses as high as
200 mg/kg have been systemically injected in rats without adverse
effects (Thompson et al., 2012).
Based upon estimated exposures to plant-derived RNA mole-
cules, the minimal oral bioavailability of oligonucleotides (Sec-
tion 3.4.5.), and the lack of oral toxicity of RNA, margins of
exposure for plant-derived siRNAs from consumption of foods
and feeds from biotech crops are anticipated to be very large, likely
in excess of 10,000 fold. Thus, even upon eating thousands of times
more grain than a conservative consumption estimate (i.e., 97.5th
percentile) of a putative RNA-based biotech crop – a physical
impossibility – no adverse effects due to the exogenous RNA would
be anticipated. Although potential risks of a new crop with traits
produced utilizing RNA-mediated gene regulation should be as-
sessed, based on the data discussed in this review we propose that
minimal risk will result from consumption of small RNAs derived
from these biotech crops.3.4.3. Evidence from mammalian and human studies with siRNA
indicates that exposure levels needed to produce systemic effects are
greater than those possible from ingestion
The promise of speciﬁcity for oligonucleotide therapeutics cre-
ated great interest in development of drugs that act through anRNAi mechanism (e.g., RNA oligonucleotide drugs); however, sys-
temic delivery of these therapeutics remains a challenge (Behlke,
2006; Nguyen et al., 2008; O’Neill et al., 2011; Vaishnaw et al.,
2010). The fact that delivery of functional RNA oligonucleotide
therapeutics is one of the major contributors to their limited suc-
cess to date suggests that biological barriers limit the activity of
exogenous RNA in humans and other mammals. In spite of these
signiﬁcant delivery challenges, several RNA drugs are currently
undergoing evaluation in Phase II and III clinical trials (Lares
et al., 2010; Vaishnaw et al., 2010). About half of these RNA-based
drugs are administered locally with the expectation of activity at
the site of application (e.g., in the eye, skin, or lung) (Vaishnaw
et al., 2010). Oligonucleotide therapeutics delivered systemically
have succeeded after extensive efforts to stabilize these oligonucle-
otides through chemical modiﬁcations that impart suitable phar-
macokinetic properties and to formulate them in specialized
lipophilic delivery vehicles (Behlke, 2006). Doses administered or
proposed to be systemically administered to subjects in clinical tri-
als have been as high as 10 mg/kg in the case of unformulated siR-
NA for prophylactic treatment of delayed graft function in renal
transplantation (Quark Pharmaceuticals, 2013) and 1.5 mg/kg in li-
pid nanoparticles for the treatment of liver cancer patients (Alny-
lam Pharmaceuticals, 2013). Preliminary readouts indicate good
tolerability and movement of compounds into Phase II studies sup-
ports the conclusion of safety. The doses used in these therapeutic
trials are orders of magnitude greater than anticipated exposures
that would result from consumption of food and feed derived from
biotech crops employing RNA-mediated gene regulation (see
Section 3.4.2.).
The drug delivery challenges experienced to date with develop-
ment of oligonucleotide-based human therapeutics provide sup-
port for the conclusion that small RNA molecules derived from
biotech crops employing an RNAi-based mechanism (e.g. siRNAs
or miRNAs) are safe to consume. Some key results from mamma-
lian in vitro and in vivo studies with small RNAs are relevant to
safety assessment of biotech crops that utilize a mechanism based
on RNAi.
First, siRNAs have relatively high speciﬁcity as repeatedly dem-
onstrated by absence of gene suppression by control siRNAs lack-
ing homology to the target gene, as well as a lack of suppression
of genes related to the gene being targeted with siRNA (Amarzgui-
oui et al., 2003; Duxbury et al., 2004; Elbashir et al., 2001; Martinez
et al., 2002). This implies that in order to induce RNA-mediated
gene suppression in the consuming species, assuming that an
exogenous dietary RNA could undergo absorption and delivery to
potential target cells, the exogenous siRNA would have to have sig-
niﬁcant sequence identity with a gene in the consuming organism.
There is also some evidence to suggest that siRNAs with comple-
mentarity to mammalian genes that are produced in and isolated
from transgenic plants may not be effective if taken up by mamma-
lian cells, possibly due to a plant-speciﬁc siRNA modiﬁcation (Chau
and Lee, 2007).
Second, most mammalian cell types do not efﬁciently take up
double-stranded nucleic acids. A small fraction of siRNAs in circu-
lation or in culture may be transported into cells through endocy-
tosis, but any free nucleic acids that enter cells largely remain
within endosomal/lysosomal vesicles and are subsequently de-
graded by nucleases (Gilmore et al., 2004). Absent transfection re-
agents, which transiently create pores in cell membranes to
facilitate uptake, naked siRNA generally fails to suppress gene
expression at concentrations as high as 250 nM (Lingor et al.,
2004). RNAi-mediated gene suppression in leukemic B-1 cells
was observed without transfection reagents, though this suppres-
sion required siRNA concentrations as high as 2 lM (McCarthy
et al., 2004). These concentrations are orders of magnitude higher
than anticipated exposures resulting from consumption of RNA in
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dsRNA molecules (See Section 3.4.5.).
Hydrodynamic injection has been described as an effective
method to deliver unformulated siRNA in vivo for target gene
silencing in mice (Lewis and Wolff, 2007). The procedure requires
a high volume solution of siRNA (typically 1–2 ml in mice) and
very rapid, high-pressure, intravenous injection of nucleic acid.
Functional delivery appears to be restricted to the liver, and deliv-
ery efﬁciency is dramatically reduced if either volume or pressure
is lowered. The dose of siRNA and the hydrostatic pressure needed
to achieve target gene silencing by unformulated siRNA exceeds
what can be encountered through dietary ingestion. In the case
of intravenous injection of naked/chemically stabilized siRNAs tar-
geting Apolipoprotein B (no delivery agent and not conjugated to a
cholesterol tag), efﬁcacy is not observed in the liver of mice follow-
ing injection of doses as high as 50 mg/kg (Soutschek et al., 2004).
In rats and monkeys, acute toxicity is not observed following i.v.
bolus doses of 200 mg/kg and 500 mg/kg of an siRNA targeting
p53, respectively (Thompson et al., 2012). A few deaths occurred
in rats after single i.v. bolus doses of 1,200 mg/kg (1/10 females)
and 2,000 mg/kg (2/10 males). Toxicities observed at 1,200 mg/kg
(e.g. erosion and/or ulcers of the glandular stomach and subacute
inﬂammation and edema of the pancreas) were completely or par-
tially reversible following a 2-week recovery period (Thompson
et al., 2012). When these study results are considered in the con-
text of the limited oral bioavailability of ingested nucleic acids,
the tested doses are quite high (5 orders of magnitude or more) rel-
ative to anticipated dietary exposures from biotech crops, making
the observed toxicity from intravenous exposures at such doses
largely irrelevant to the safety of these ingested nucleic acids.
The observed no effect levels also appear to establish a large mar-
gin of exposure for orally ingested small RNA molecules from bio-
tech crops. Effective gene suppression or toxicity in an exposed
organism following dietary exposure to siRNAs or longer dsRNAs
would thus require exceedingly high levels of the RNA and signif-
icant sequence identity with the consuming organism, both of
which are highly unlikely to result from applications of RNA-med-
iated gene regulation in biotech crops.
3.4.4. Unmodiﬁed siRNAs are metabolically unstable in biological
matrices and undergo rapid clearance
In addition to empirical data supporting the history of safe con-
sumption of RNA from plants (and animal products), there is a
wealth of data indicating that RNA molecules have a very short
half-life in mammalian systems (Behlke, 2006; Molitoris et al.,
2009; Thompson et al., 2012; Vaishnaw et al., 2010). RNA mole-
cules have limited stability in biological matrices such as saliva,
serum, and plasma. In the case of siRNA duplexes without any
chemical modiﬁcations, signiﬁcant degradation occurs in as little
as 15 min when the siRNA is incubated in fetal calf or human sera
(Haupenthal et al., 2006; Urban-Klein et al., 2005). In the absence
of stabilizing modiﬁcations, siRNA in human plasma is rapidly de-
graded with nearly 75% degraded within 2 min (Layzer et al.,
2004), most likely due to nucleases and to the chemical environ-
ment (e.g. pH). This metabolic instability is one factor that reduces
the likelihood that ingested dsRNAs or siRNAs will have biological
activity.
Although intravenous injection is the most effective means of
delivering a drug to the systemic circulation, because it bypasses
the need for systemic absorption, unformulated RNA molecules
have been shown to lack systemic activity via this route due in part
to rapid renal ﬁltration and excretion (Braasch et al., 2004; Molito-
ris et al., 2009; Soutschek et al., 2004; Vaishnaw et al., 2010).
Although metabolic stability can be altered with chemical modiﬁ-
cations (as is the case of the siRNAs in clinical trials), even chemi-
cally stabilized siRNAs have limited or no systemic biologicalactivity after injection because of other factors that limit cellular
uptake, such as rapid plasma clearance (Vaishnaw et al., 2010).
Because molecules less than the molecular weight of albumin
(67kD) pass through the molecular sieve of the glomerulus, dsR-
NAs, including siRNAs, are rapidly ﬁltered from blood and excreted
in the urine. An siRNA injected into mice exhibited a half-life of
6 min and a high rate of clearance (Vaishnaw et al., 2010). This
property of siRNA molecules was conﬁrmed with vital microscopy:
siRNA can be visualized in renal ﬁltrate within seconds after injec-
tion (Molitoris et al., 2009). Following intravenous injections of an
anti-p53 siRNA in rats at doses up to 200 mg/kg, plasma siRNA con-
centrations declined by >90% within 30 min (relative to levels at
5 min post dose) and declined by >98% within 2 h (Thompson
et al., 2012). Only about 1–2% of the intravenously administered
dose is absorbed by tissues and the majority of this uptake occurs
in the kidney (Thompson et al., 2012). Most of the siRNA is cleared
from tissues within 30 h of dosing (below the lower limit of quan-
tiﬁcation in 6 of 9 extra-renal tissues evaluated) and there is no
indication of siRNA accumulation in tissues. These data illustrate
the limited biodistribution and the high clearance rate of injected
nucleic acids in mammalian systems and demonstrate that most
of the material is excreted or metabolized within hours. By infer-
ence from the pharmacokinetic properties of injected siRNAs, only
a very small fraction of ingested dsRNA or siRNA, should it undergo
absorption into the systemic circulation, would be likely to under-
go distribution to tissues.
3.4.5. Biological barriers to oral activity of dietary small RNAs and
longer dsRNAs
As described above, nucleic acids are ubiquitous components of
the diets of nearly all animals. Not surprisingly, there are a number
of biological barriers to oral activity of these ingestedRNAmolecules
(Fig. 1). The ﬁrst barriers encountered by ingested nucleic acids are
salivary RNases (Park et al., 2006) and the harsh acidic conditions of
the stomach that denature and depurinate nucleic acids (Loretz
et al., 2006; O’Neill et al., 2011). Nucleases in the lumen of the gas-
trointestinal tract and degradative enzymes (and possibly bile salts)
frompancreatic secretions into theduodenumalsodegrade ingested
nucleic acids into nutritionally bioavailable nucleotides (O’Neill
et al., 2011). The gut also provides a physical barrier to uptake of
hydrophilic compounds like siRNAs. Therefore, systemic delivery
of RNA via the oral route is difﬁcult to achieve due to rapid degrada-
tion andpoor transcytosis across themammalian gut. In the absence
of encapsulation to prevent degradation, or addition of chemical sta-
bilization and penetration enhancers, absorption of RNA, including
siRNAs, across the gastrointestinal tract is negligible (Akhtar,
2009; Jain, 2008). In addition, the lowpercentage of ingested nucleic
acids that might be systemically absorbed from the gastrointestinal
tract must escape nucleases in the blood (Houck, 1958) and renal
clearance (Molitoris et al., 2009). In the unlikely event that signiﬁ-
cant quantities of ingestednucleic acids are absorbed across the gas-
trointestinal tract and undergo distribution to tissues, in order to
affect gene expression these molecules must: (1) cross cellular
membranes that pose a signiﬁcant barrier to uptake; (2) escape from
early endosomes to enter the cytoplasm; and (3) avoid degradation
by nucleases foundwithin lysosomes (Gilmore et al., 2004;Manjun-
ath and Dykxhoorn, 2010; Sioud, 2005). Each of the above biological
barrierswould be expected to reduce levels of intact, biologically ac-
tive siRNAs by an order ofmagnitude ormore such that the cumula-
tive impact of all these barriers would result in an insufﬁcient
amount of intact siRNA to impact cellular function. This level of
understanding of these biological barriers is consistent with the
pharmaceutical industry experiences illustrating limited delivery
of therapeutic RNAs.
Although strong evidence provided by pharmaceutical company
and academic studies indicates a low potential for oral activity of
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may be possible for certain highly expressed plant miRNAs (Zhang
et al., 2012a). This study reported that in mice fed a diet consisting
entirely of uncooked rice (i.e., human equivalent of about 33 kg/
day of cooked rice1), several rice miRNAs were detectable in mouse
serum and liver. Although the levels of a mouse mRNA with se-
quence identity to a rice miRNA (miR168a) were not affected follow-
ing consumption of rice, the authors report that levels of the encoded
protein, low density lipoprotein receptor adaptor protein 1, were
lower in mice fed raw rice than in mice fed a standard rodent chow
diet. This study also reported increases in plasma low density lipo-
protein (LDL) cholesterol levels and attributed them to changes in
levels of this adaptor protein resulting from rice miR168a ingestion.
However, in a 90 day rat feeding study with 70% rice formulated into
a nutritionally balanced diet, LDL levels remained unchanged rela-
tive to control rats (Zhou et al., 2011b). Additionally, in another
study, rats fed 70% rice (formulated into a nutritionally balanced
diet) over three generations had reduced LDL levels relative to con-
trol rats (Zhou et al., 2012). Blood cholesterol levels are known to be
impacted in rodents by differences in dietary composition during
fasting and re-feeding (Ryu et al., 2005). The increase in LDL levels
observed by Zhang and colleagues most likely resulted from the
short-term nutritional impact of consuming only rice following a
fasting period, rather than miR168a ingestion, as such a dietary reg-
imen would be lower in fat, cholesterol, and protein than one con-
sisting of a standard rodent chow.
Zhang and colleagues did not report any adverse physiological
or toxicological effects, and the observed differences in LDL choles-
terol values were not evaluated within the context of historical val-
ues for this parameter in mice. Furthermore, this study (Zhang
et al., 2012a) was conducted using high levels of rice that were
not reﬂective of anticipated dietary exposure levels and the
authors state: ‘‘It is unlikely that such high concentrations of ma-
ture plant miRNAs can be achieved in serum, plasma, and organs
of humans or animals via food intake.’’
In a study that identiﬁed plant miRNAs in publicly available
small RNA datasets from mammals (including cultured human
cells), chicken and insects (Zhang et al., 2012c), miR168 was highly
over-represented even though it is not the most abundant miRNA
in staple food/feed crops. Additionally,P96% of miR168 sequences
observed in this study were monocot-derived (the sequence is
divergent from the dicot sequence), including those from two in-
sects fed only dicot plant materials (Zhang et al., 2012c). The
authors of this study therefore concluded that plant miRNAs iden-
tiﬁed in animal small RNA sequencing data can originate from arti-
facts of the sequencing process. Although the phenomenon of oral
uptake and activity of dietary miRNAs merits further conﬁrmation
and evaluation, the weight-of-the-evidence does not suggest that
miRNAs derived from normal dietary exposure have a meaningful
impact on mammalian or human gene regulation.
Despite extensive pharmaceutical and academic research ef-
forts to develop therapeutics based on modulation of gene expres-
sion by siRNAs, there are an extremely limited number of
published reports documenting effective oral administration of
siRNAs for the modulation of gene expression in mammals and
these studies utilize highly specialized carrier molecules (O’Neill
et al., 2011). Chemically modiﬁed antisense DNA oligonucleotides
formulated with caprate, a well-known permeation enhancer, pro-
duced average plasma bioavailability of 9.5% in humans across four
formulations (Tillman et al., 2008). In the case of a 20-mer DNA oli-1 Mice in the Zhang et al. study ate 7 g of rice per day and this calculation
assumes mouse body weight of 30 g. The calculations were made assuming a 55 kg
body weight for Chinese adults and 2.57-fold more miR168a in raw rice vs. cooked
rice as reported by Zhang and colleagues in their supplementary data; therefore, 7 g
rice  55 kg  2.57/0.03 kg = 33 kg cooked rice equivalents.gonucleotide with stabilizing phosphorothioate internucleotide
linkages in the backbone, but delivered without a permeation en-
hancer, oral bioavailability of the radioactively labeled oligonu-
cleotide in rats was only 0.1% (Nicklin et al., 1998). This number
is likely to overestimate bioavailability because it was based on
measurement of radiolabel rather than intact oligonucleotide
(fragments would retain the label) and because the oligonucleotide
was chemically modiﬁed to enhance stability. In the case of an-
other unformulated phosphorothioate DNA oligonucleotide (i.e.,
no delivery agent), intestinal absorption of less than 1% of dose
was observed in an isolated rat intestinal model (a model that by-
passes the harsh conditions of the stomach); most of the labeled
oligonucleotide was associated with the outer (epithelial cell)
membrane, and very little was localized intracellularly (Khatsenko
et al., 2000). Limited oral bioavailability of nucleic acid therapeu-
tics coupled with the presence of internal biological barriers to
activity of exogenous RNA (e.g., nucleases, cellular membranes,
and endosomes) have made systemic delivery of orally adminis-
tered oligonucleotide drugs an elusive goal for the pharmaceutical
industry. This limited oral bioavailability provides support for our
conclusion of oral safety for dietary exposures to small dsRNAs,
longer dsRNAs, and other nucleic acids resulting from agricultural
applications of RNAi.
In addition to any potential systemic effects of ingested siRNAs
and other dsRNAs, the possibility for effects of these dietary con-
stituents on gastrointestinal tissues merits consideration. Available
data from single-stranded phosphorothioate DNA oligonucleotide
studies demonstrate that oligonucleotides in the intestinal tract
are primarily located extracellularly (e.g., in lumen and luminal
wall) (Khatsenko et al., 2000; Nicklin et al., 1998) and are thus pre-
sumed to be excreted from the body with minimal absorption. Due
to RNA degradation by nucleases and biological barriers to cellular
uptake, only a very small fraction of ingested nucleic acid (about
0.1% following oral dosing of a DNA oligonucleotide) is absorbed
across the intestinal epithelium (Nicklin et al., 1998). Only a very
small fraction of the absorbed RNA will escape sequestration by
endosomes or degradation by nucleases and become available for
RISC incorporation – all prerequisites for RNA-mediated gene sup-
pression. Thus, when metabolism and barriers to RNA absorption
are taken into account, it is unlikely that dietary dsRNAs are pres-
ent in sufﬁcient quantities to mediate systemic effects or local ef-
fects on the cells of the mammalian intestinal tract.
3.5. Speciﬁcity of RNA-mediated gene suppression
RNA-mediated gene suppression is hybridization-dependent
and thus occurs in a sequence-speciﬁc manner; however, suppres-
sion of genes with less than perfect complementarity has been doc-
umented in in vitro mammalian screening assays (Jackson et al.,
2003; Jackson et al., 2006a; Jackson et al., 2006b; Vaishnaw et al.,
2010). Off-target gene suppression can occur through hybridiza-
tion with genes that have a high degree of sequence similarity to
the intended target gene, especially between the siRNA ‘‘seed re-
gion’’ (nucleotides 2–8 of the guide strand) and the 30 untranslated
region of an off-target gene (Jackson et al., 2006b). The seed region
is critical for mRNA recognition by RISC-incorporated small RNAs.
Seed pairing has been shown to be necessary and sufﬁcient for tar-
get regulation by some miRNAs (Doench and Sharp, 2004; Krek
et al., 2005; Lewis et al., 2005; Lewis et al., 2003), and a single base
mismatch within the seed region of the siRNA may eliminate
detectable siRNA-mediated silencing of the target (Amarzguioui
et al., 2003; Du et al., 2005). However, sequence complementarity
outside the seed region is also required for efﬁcient target suppres-
sion by siRNAs and some miRNAs (Didiano and Hobert, 2006; Ha
et al., 1996; Tay et al., 2008; Vella et al., 2004), and single base
mutations outside the seed region can in some cases eliminate
174 J.S. Petrick et al. / Regulatory Toxicology and Pharmacology 66 (2013) 167–176target suppression (Du et al., 2005; Duxbury et al., 2004; Elbashir
et al., 2001). In addition, factors such as site context and sequence
context contribute to the efﬁcacy of target silencing (Grimson
et al., 2007). Therefore, a match between the seed region and a tar-
get gene is not necessarily sufﬁcient for gene suppression. The po-
tency of hybridization-dependent off-target gene suppression
appears to be several orders of magnitude lower than on-target
gene suppression and changes in transcriptional proﬁles (i.e., off-
target regulation of gene expression) have not been shown to im-
pact in vivo safety in preclinical studies (Vaishnaw et al., 2010).
When these phenomena are considered together with low expo-
sures and biological barriers to ingested RNA, there appears to be
a very low likelihood for any toxicologically relevant off-target
gene suppression effects in humans or animals due to applications
of RNAi or related gene suppression methods in biotech crops.3.6. Potential for RNA induction of the interferon response
Initiation of the interferon response and inﬂammatory re-
sponses due to siRNA administration have been reported in mam-
malian in vitro systems and following systemic administration of
siRNAs in animal models (Judge and MacLachlan, 2008; Robbins
et al., 2009). These responses are mediated by receptors that inter-
act with dsRNA such as the Toll-like receptors, the dsRNA binding
protein kinase PKR, and the RIG-I and MDA-5 RNA helicases. The
induction of this response is inﬂuenced by nucleotide sequence
and dose of the oligonucleotide, route of delivery, and cell type
but interferon induction does not result from gene suppression.
Some of these effects appear to be due to liposomal or polycation
delivery vehicles and/or chemical modiﬁcations to the siRNA back-
bone, rather than to the siRNA itself (Heidel et al., 2004; Judge and
MacLachlan, 2008; Ma et al., 2005). Unmodiﬁed dsRNA can trigger
an innate immune response in a sequence- and structure-depen-
dent manner (Jackson and Linsley, 2010); however, there are no re-
ports to date of interferon or inﬂammatory responses following
oral exposure to siRNAs or other nucleic acids. In the case of an siR-
NA delivered orally to mice (encapusulated in a specialized deliv-
ery vehicle), immunostimulation was not observed in the
presence of target gene suppression (Aouadi et al., 2009). Immuno-
stimulation from an ingested RNA would require absorption of a
given RNA to a sufﬁcient concentration for induction of the re-
sponse, a phenomenon that is improbable given the multitude of
biological barriers to attainment of signiﬁcant levels of systemic
RNA after dietary RNA consumption. The history of safe consump-
tion of RNA from a variety of dietary sources also supports the con-
clusion that immunostimulation following dietary exposure to
RNA is highly unlikely.4. Conclusions
Available data strongly support the conclusion that biotechnol-
ogy-derived crops employing RNA-mediated gene regulation are
safe for human and animal consumption. Nucleic acids are natural
components of all foods and feeds and are therefore presumed to
be safe based on their long history of safe consumption. There
are extensive biological barriers to absorption and cellular uptake
of dietary nucleic acids (i.e., components larger than single nucle-
otides), as well as rapid catabolism and/or excretion of nucleic
acids. Preclinical and clinical data on systemic delivery of oligonu-
cleotide therapeutics indicates that cellular uptake is limited and
that these agents are generally well tolerated. Therefore, applica-
tion of the existing comparative safety assessment paradigm to
those crops engineered using RNA-mediated gene regulation is
appropriate. This safety assessment paradigm involves a compari-
son of various characteristics of the biotechnology-derived cropwith those of the conventional counterpart including characteriza-
tion of the genetic modiﬁcation, plant agronomic and morphologic
characteristics, and crop composition. A scientiﬁcally valid, test-
able hypothesis should drive any additional safety testing (e.g., ani-
mal feeding or additional safety studies) for biotech crops
expressing constructs that elicit RNA-mediated gene regulation.Conﬂict of interest
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